Dose-adjusted EPOCH-R compared with R-CHOP as frontline therapy for diffuse large B-cell lymphoma: Clinical outcomes of the Phase III intergroup trial alliance/CALGB 50303 Academic Article uri icon

Overview

MeSH Major

  • Bone Marrow Neoplasms
  • Burkitt Lymphoma
  • Central Nervous System Neoplasms
  • DNA-Binding Proteins
  • Gene Rearrangement
  • Genes, bcl-2
  • Genes, myc
  • Germinal Center
  • Lymphoma, Large B-Cell, Diffuse

abstract

  • In the 50303 study population, the more intensive, infusional DA-EPOCH-R was more toxic and did not improve PFS or OS compared with R-CHOP. The more favorable results with R-CHOP compared with historical controls suggest a potential patient selection bias and may preclude generalizability of results to specific risk subgroups.

publication date

  • July 20, 2019

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1200/JCO.18.01994

PubMed ID

  • 30939090

Additional Document Info

start page

  • 1790

end page

  • 1799

volume

  • 37

number

  • 21